✦ LIBER ✦

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

✍ Scribed by Lee M. Krug; Vincent A. Miller; Jyoti Patel; John Crapanzano; Christopher G. Azzoli; Jorge Gomez; Mark G. Kris; Robert T. Heelan; Barbara Pizzo; Leslie Tyson; Christine Sheehan; Jeffrey S. Ross; Ennapadam Venkatraman

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 111 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21428

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of weekly docetaxel plu

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma

✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch

Phase II study of weekly irinotecan plus

Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma

✍ Ji-Youn Han; Dae Ho Lee; Sung Young Lee; Chun Gun Park; Hyae Young Kim; Hong Gi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

Weekly docetaxel in the treatment of eld

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Lisa H. Morrissey; Jo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme

A phase II study of gemcitabine plus ora

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Tony S. K. Mok; Benny Zee; Anthony T. C. Chan; Winnie Yeo; Wei Tse Yang; Anthony 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 3 views

Randomized phase 2 study of irinotecan p

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer

✍ Ji-Youn Han; Dae Ho Lee; Jung Eun Song; Sung Young Lee; Hyae Young Kim; Heung Ta 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

Weekly docetaxel versus docetaxel/gemcit

Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer : A randomized phase 3 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; David R. Spigel; Cindy Farley; Dianna L. Shipley; James D. B 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract ## BACKGROUND. The aim of this study was to compare the efficacy of single‐agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Previously untreated pat